Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...
Asianet Newsable on MSN
New Drug Cuts Bad Cholesterol by Nearly 60% in First-Year Trials
Discover Enlicitide, a new daily pill for genetic high cholesterol (HeFH). A recent trial shows it lowers bad LDL cholesterol ...
NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment ...
Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...
In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...
Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...
When added to optimized oral anti-lipid therapy, a PCSK9 blocker provided an additional 25% risk reduction in a first cardiovascular event, new data show.
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...
Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback